Cetirizine Sustained Release Capsules

This product is a compound preparation composed of cetirizine hydrochloride and pseudoephedrine hydrochloride. Cetirizine is a selective histamine H1 receptor antagonist. It has no obvious anticholinergic and anti-5-hydroxytryptamine effects, and has a small central inhibitory effect; pseudoephedrine hydrochloride is an adrenergic drug that can constrict nasal mucosal blood vessels and relieve symptoms of nasal congestion and runny nose.

This product is a compound preparation, its components are: cetirizine hydrochloride, pseudoephedrine hydrochloride. Each tablet contains 5mg of cetirizine hydrochloride and 120mg of pseudoephedrine hydrochloride.

This product is a hard capsule, and the contents are off-white spherical pellets.

This product is used to relieve nasal or non-nasal symptoms caused by perennial or seasonal allergic rhinitis.

Oral administration. This sustained-release tablet is swallowed whole and should not be broken or chewed. Adults and children over 12 years old, 1 tablet each time, 2 times a day. Take before or after meals. Dosage adjustment for patients with renal and liver impairment: For patients with renal impairment (creatinine clearance 11-31 ml/min), hemodialysis patients (creatinine clearance less than 7 ml/min) and patients with liver impairment, it is recommended to take one tablet once a day.

Cetirizine hydrochloride: Occasionally, drowsiness, headache, fatigue, dry mouth, nausea, and sedation may occur. Overdose may cause fatal arrhythmias. Pseudoephedrine hydrochloride: It is a sympathomimetic drug. It may increase the incidence of blurred vision, headache, irritability, insomnia, nausea, vomiting, thirst, palpitations, and frequent urination. Illusions and hallucinations may occur, and some may develop into arrhythmias, circulatory failure, palpitations, coma, and respiratory failure. For highly sensitive patients, it may cause mild central nervous system symptoms such as nervousness, insomnia, blurred vision, excitement, dizziness, and fatigue. Headache, nausea, drowsiness, palpitations, blood pressure fluctuations, arrhythmia, etc. have been reported. At the same time, sympathomimetic drugs may also cause hallucinations, tension, tremors, difficulty breathing, difficulty urinating, circulatory failure, etc.

This product is contraindicated in patients with allergic or idiosyncratic reactions to the ingredients contained in this product, hydroxyzine, adrenergic drugs or other drugs with similar chemical structures. This product is contraindicated in patients who are currently receiving monoamine oxidase inhibitors or have received such treatment within 14 days or have just stopped such treatment. This product is also contraindicated in patients with narrow-angle <ahref=http://jbk.39.net/keshi/wuguan/yanke/4fab1.html

Pharmacokinetic interaction studies of cetirizine in adults have shown that antipyrine, ketoconazole, erythromycin and azithromycin have no interaction with cetirizine. Studies on multiple doses of theophylline (400 mg once a day for 3 consecutive days) and cetirizine (20 mg once a day for 3 consecutive days) have shown that the body clearance of cetirizine decreased by 16%. It is speculated that larger doses of theophylline may have a greater effect. The distribution of theophylline is not changed by the presence of cetirizine. The simultaneous use of antihypertensive drugs with sympathetic inhibition (such as methyldopa, reserpine, etc.) will reduce the latter's hypotensive effect. Pseudoephedrine can increase ectopic pacemaker activity when used simultaneously with digitalis.

Validity period: 18 months

Each tablet contains 5mg of cetirizine hydrochloride and 120mg of pseudoephedrine hydrochloride

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

• Founded in:

  1997-04-28

• Address:

  No. 38 Huanghe Road, Lianyungang Economic and Technological Development Zone

• Tax NO.:

  9132070070404786XB

• Registered Funds:

  6,379,002,274 yuan

• Website:

  Log in to view

• Email:

  Log in to view